Skip to main content
Ernexa Therapeutics Inc. logo

Ernexa Therapeutics Inc. — Investor Relations & Filings

Ticker · ERNA ISIN · US6294106066 US Manufacturing
Open in API
Filings indexed 1,027 across all filing types
Latest filing 2025-07-07 Director's Dealing
Country US United States of America
Listing US ERNA

About Ernexa Therapeutics Inc.

https://www.ernexatx.com/

Ernexa Therapeutics Inc. is a biopharmaceutical company developing cell therapies for advanced cancer and autoimmune diseases. The company's core technology platform engineers induced pluripotent stem cells (iPSCs) and differentiates them into induced mesenchymal stem cells (iMSCs). These engineered iMSCs are designed as scalable, off-the-shelf treatments that leverage the natural ability of MSCs to home to sites of tumors or inflammation. Once at the target site, the cells deliver therapeutic payloads, such as cytokines, to modulate the immune system. The company's lead candidate, ERNA-101, is being developed for the treatment of ovarian cancer. Its pipeline also includes ERNA-201, a cell therapy designed to target inflammation in autoimmune diseases.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-07-07 English
8-K
Audit Report / Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 30, 2025, by Ernexa Therapeutics Inc. The content focuses on the dismissal of the former independent registered public accounting firm (Grant Thornton LLP) and the appointment of a new independent registered public accounting firm (Haskell & White LLP). It includes details about the audit reports, disagreements, and reportable events related to the accounting firms. This type of filing is specifically about changes in the company's certifying accountant, which falls under audit-related information but is not a full audit report or annual report. It is a current report on a significant event related to audit firm changes. Therefore, the most appropriate classification is Audit Report / Information (AR). The document length (6963 characters) and detailed content support that this is a substantive filing, not just an announcement or certification letter. Hence, confidence is high.
2025-07-07 English
Regulatory Filings 2025
Regulatory Filings
2025-06-20 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) under the Securities Act of 1933. It details the registration of shares for resale by selling stockholders, including information about a private placement, registration rights agreement, and resale of shares and pre-funded warrants. The document includes sections such as "Risk Factors," "Plan of Distribution," and "Use of Proceeds," which are typical components of a prospectus related to securities registration and resale. It is not an annual report, earnings release, or management discussion, nor is it a proxy statement or voting results announcement. The document is a detailed offering prospectus for resale of shares, which fits the category of a Capital/Financing Update (CAP) as it relates to securities registration and capital market transactions. The length (15,000 characters) and content confirm it is the actual prospectus, not just an announcement of a report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-06-18 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter from Ernexa Therapeutics Inc. to the SEC requesting acceleration of the effectiveness of a Registration Statement on Form S-3. It is a regulatory communication related to securities registration and does not contain financial statements or detailed financial data. The document length is short (942 characters), and it is a formal request rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-06-16 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. The text is not interpretable as a financial report, announcement, or any specific filing type. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS), which serves as a catch-all category for filings that do not fit other specific categories.
2025-06-16 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.